Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study

被引：21

作者：

Santoni, Matteo ^{[1
]}

Massari, Francesco ^{[2
]}

Myint, Zin W. ^{[3
]}

Iacovelli, Roberto ^{[4
]}

Pichler, Martin ^{[5
]}

Basso, Umberto ^{[6
]}

Kopecky, Jindrich ^{[7
]}

Kucharz, Jakub ^{[8
]}

Buti, Sebastiano ^{[9
]}

Rizzo, Mimma ^{[10
]}

Galli, Luca ^{[11
]}

Buettner, Thomas ^{[12
]}

De Giorgi, Ugo ^{[13
]}

Kanesvaran, Ravindran ^{[14
]}

Fiala, Ondrej ^{[15
]}

Grande, Enrique ^{[16
]}

Zucali, Paolo Andrea ^{[17
,18
]}

Fornarini, Giuseppe ^{[19
]}

Bourlon, Maria T. ^{[20
]}

Scagliarini, Sarah ^{[21
]}

Molina-Cerrillo, Javier ^{[22
]}

Aurilio, Gaetano ^{[23
]}

Matrana, Marc R. ^{[24
]}

Pichler, Renate ^{[25
]}

Cattrini, Carlo ^{[26
]}

Buechler, Tomas ^{[27
]}

Seront, Emmanuel ^{[28
]}

Calabro, Fabio ^{[29
]}

Pinto, Alvaro ^{[30
]}

Berardi, Rossana ^{[31
]}

Zgura, Anca ^{[32
]}

Mammone, Giulia ^{[33
]}

Ansari, Jawaher ^{[34
]}

Atzori, Francesco ^{[35
]}

Chiari, Rita ^{[36
]}

Bamias, Aristotelis ^{[37
]}

Caffo, Orazio ^{[38
]}

Procopio, Giuseppe ^{[39
,40
]}

Bassanelli, Maria ^{[41
]}

Merler, Sara ^{[42
]}

Messina, Carlo ^{[43
]}

Kueronya, Zsofia ^{[44
]}

Mosca, Alessandra ^{[45
]}

Bhuva, Dipen ^{[46
]}

Vau, Nuno ^{[47
]}

Incorvaia, Lorena ^{[48
]}

Rebuzzi, Sara Elena ^{[49
,50
]}

Roviello, Giandomenico ^{[51
]}

Zabalza, Ignacio Ortego ^{[16
]}

Rizzo, Alessandro ^{[52
]}

机构：

[1] Macerata Hosp, Oncol Unit, Via Santa Lucia 2, I-62100 Macerata, Italy

[2] IRCCS Azienda Osped Univ Bologna, Med Oncol, Via Albertoni 15, Bologna, Italy

[3] Univ Kentucky, Markey Canc Ctr, Lexington, KY 40536 USA

[4] Fdn Policlin Univ Agostino Gemelli IRCCS, Oncol Med, Rome, Italy

[5] Med Univ Graz, Dept Internal Med, Div Oncol, Augenbruggerplatz 15, A-8010 Graz, Austria

[6] Ist Oncol Veneto IOV IRCCS, Dept Oncol, Oncol Unit 3, Padua, Italy

[7] Univ Hosp Hradec Kralove, Dept Clin Oncol & Radiotherapy, Hradec Kralove, Czech Republic

[8] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Uro Oncol, Warsaw, Poland

[9] Univ Parma, Univ Hosp Parma, Dept Med & Surg, Med Oncol Unit, Parma, Italy

[10] AOU Consorziale Policlin Bari, Div Med Oncol, Piazza G Cesare 11, I-70124 Bari, Italy

[11] Univ Hosp Pisa, Oncol Unit 2, I-56126 Pisa, Italy

[12] Univ Hosp Bonn UKB, Dept Urol, D-53127 Bonn, Germany

[13] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amador, Dept Med Oncol, Meldola, Italy

[14] Natl Canc Ctr Singapore, Div Med Oncol, Singapore, Singapore

[15] Charles Univ Prague, Univ Hosp Pilsen, Fac Med, Dept Oncol & Radiotherapeut, Plzen, Czech Republic

[16] MD Anderson Canc Ctr Madrid, Dept Med Oncol, Madrid, Spain

[17] Humanitas Univ, Dept Biomed Sci, Pieve Emanuele, Milan, Italy

[18] IRCCS Humanitas Res Hosp, Dept Oncol, Milan, Italy

[19] IRCCS Osped Policlin San Martino, Genoa, Italy

[20] Inst Nacl Ciencias Med & Nutr Salvador Zubiran, Hematol & Oncol Dept, Mexico City, Mexico

[21] Azienda Osped Rilievo Nazl Cardarelli Napoli, UOC Oncol, Naples, Italy

[22] Hosp Ramon & Cajal, Dept Med Oncol, Madrid, Spain

[23] European Inst Oncol IRCCS, Med Oncol Div Urogenital & Head & Neck Tumours, IEO, Milan, Italy

[24] Ochsner Med Ctr, Dept Internal Med, Hematol Oncol, New Orleans, LA USA

[25] Med Univ Innsbruck, Dept Urol, Anichstr 35, A-6020 Innsbruck, Austria

[26] Maggiore Car Univ Hosp, Dept Med Oncol, I-28100 Novara, Italy

[27] Charles Univ Prague, Thomayer Univ Hosp, Fac Med 1, Dept Oncol, Prague 14059, Czech Republic

[28] Ctr Hospitalier Jolimont, Dept Med Oncol, Haine St Paul, Haine Saint Paul, Belgium

[29] San Camillo Forlanini Hosp, Dept Oncol, Rome, Italy

[30] La Paz Univ Hosp, Med Oncol Dept, Madrid, Spain

[31] Univ Politecn Marche, Dept Med Oncol, AOU Ospedali Riuniti Marche, Ancona, Italy

[32] Carol Davila Univ Med & Pharm, Prof Dr Alexandru Trestioreanu Inst Oncol, Dept Oncol Radiotherapy, Bucharest, Romania

[33] Sapienza Univ Rome, Dept Radiol Oncol & Anatomo Pathol Sci, Viale Regina Elena 324, I-00185 Rome, Italy

[34] Tawam Hosp, Med Oncol, Al Ain, U Arab Emirates

[35] Azienda Osped Univ Cagliari, Unita Oncol Med, Cagliari, Italy

[36] Azienda Osped Ospedali Riuniti Marche Nord, UOC Oncol, Tuscany, Italy

[37] Natl & Kapodistrian Univ Athens, ATTIKON Univ Hosp, Sch Med, Propaedeut Dept Internal Med 2, Athens, Greece

[38] Santa Chiara Hosp, Med Oncol Unit, Trento, Italy

[39] Fdn IRCCS Ist Nazl Tumori, Dipartimento Oncol Med, Milan, Italy

[40] Osped Maggiore Cremona, Oncol Med, Cremona, Italy

[41] IRCCS Regina Elena Natl Canc Inst, Med Oncol 1, Rome, Italy

[42] Univ Verona, Verona Univ Hosp Trust, Dept Med, Sect Oncol,Sch Med, Verona, Italy

[43] ARNAS Civ, Oncol Unit, Palermo, Italy

[44] Natl Inst Oncol, Dept Genitourinary Med Oncol & Clin Pharmacol, Budapest, Hungary

[45] IRCCS FPO, Candiolo Canc Inst, Oncol, I-10060 Turin, Italy

[46] Army Hosp Res & Referral, Dept Med Oncol, New Delhi, India

[47] Champalimaud Clin Ctr, Urol Oncol, P-1400038 Lisbon, Portugal

[48] Univ Palermo, Dept Surg Oncol & Oral Sci, Sect Med Oncol, Palermo, Italy

[49] Osped San Paolo, Med Oncol, I-17100 Savona, Italy

[50] Univ Genoa, Dept Internal Med & Med Specialties DiMI, Genoa, Italy

来源：

TARGETED ONCOLOGY | 2023年 / 18卷 / 04期

关键词：

CYTOREDUCTIVE NEPHRECTOMY; SUNITINIB; CANCER;

D O I：

10.1007/s11523-023-00978-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundImmuno-oncology combinations have achieved survival benefits in patients with metastatic renal cell carcinoma (mRCC).ObjectiveThe ARON-1 study (NCT05287464) was designed to globally collect real-world data on the use of immuno-combinations as first-line therapy for mRCC patients.Patients and MethodsPatients aged & GE; 18 years with a cytologically and/or histologically confirmed diagnosis of mRCC treated with first-line immuno-combination therapies were retrospectively included from 47 International Institutions from 16 countries. Patients were assessed for overall survival (OS), progression-free survival (PFS), and overall clinical benefit (OCB).ResultsA total of 729 patients were included; tumor histology was clear-cell RCC in 86% of cases; 313 patients received dual immuno-oncology (IO + IO) therapy while 416 were treated with IO-tyrosine kinase inhibitor (IO + TKI) combinations. In the overall study population, the median OS and PFS were 36.5 and 15.0 months, respectively. The median OS was longer with IO+TKI compared with IO+IO therapy in the 616 patients with intermediate/poor International mRCC Database Consortium (IMDC) risk criteria (55.7 vs 29.7 months; p = 0.045). OCB was 84% for IO+TKI and 72% for IO + IO combination (p < 0.001).ConclusionsOur study may suggest that immuno-oncology combinations are effective as first-line therapy in the mRCC real-world context, showing outcome differences between IO + IO and IO + TKI combinations in mRCC subpopulations.

引用

页码：559 / 570

页数：12

共 50 条

[21] Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project
Rizzo, Alessandro
Buti, Sebastiano
Giannatempo, Patrizia
Salah, Samer
Molina-Cerrillo, Javier
Massari, Francesco
Kopp, Ray Manneh
Fiala, Ondrej
Galli, Luca
Myint, Zin W.
Tural, Deniz
Soares, Andrey
Pichler, Renate
Mennitto, Alessia
Abahssain, Halima
Calabro, Fabio
Monteiro, Fernando Sabino M.
Albano, Anna
Mollica, Veronica
Giudice, Giulia Claire
Takeshita, Hideki
Santoni, Matteo
CLINICAL & EXPERIMENTAL METASTASIS, 2024, 41 (05) : 655 - 665
[22] Real-world Clinical Outcomes of Pazopanib Immediately After Discontinuation of Immunotherapy for Advanced Renal Cell Carcinoma
Cao, Xiting
Tang, Derek
Ratto, Barbara
Poole, Austin
Ravichandran, Shoba
Jin, Lixian
Gao, Wei
Swallow, Elyse
Vogelzang, Nicholas J.
CLINICAL GENITOURINARY CANCER, 2020, 18 (01) : E37 - E45
[23] Real-World Treatment Patterns and Outcomes in Patients Receiving Second-Line Therapy for Advanced/Metastatic Esophageal Squamous Cell Carcinoma
Abraham, Pranav
Gricar, Joe
Zhang, Ying
Shankaran, Veena
ADVANCES IN THERAPY, 2020, 37 (07) : 3392 - 3403
[24] Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
Massari, Francesco
Santoni, Matteo
Takeshita, Hideki
Okada, Yohei
Tapia, Jose Carlos
Basso, Umberto
Maruzzo, Marco
Scagliarini, Sarah
Buettner, Thomas
Fornarini, Giuseppe
Myint, Zin W.
Galli, Luca
Souza, Vinicius Carrera
Pichler, Renate
De Giorgi, Ugo
Gandur, Nathalia
Lam, Elaine T.
Gilbert, Danielle
Popovic, Lazar
Grande, Enrique
Mammone, Giulia
Berardi, Rossana
Crabb, Simon J.
Kemp, Robert
Molina-Cerrillo, Javier
Freitas, Marcelo
Luz, Murilo
Iacovelli, Roberto
Calabro, Fabio
Tural, Deniz
Atzori, Francesco
Kueronya, Zsofia
Chiari, Rita
Campos, Saul
Caffo, Orazio
Fay, Andre P.
Kucharz, Jakub
Zucali, Paolo Andrea
Rinck, Jose Augusto
Zeppellini, Annalisa
Bastos, Diogo Assed
Aurilio, Gaetano
Mota, Augusto
Trindade, Karine
Ortega, Cinzia
Sade, Juan Pablo
Rizzo, Mimma
Fiala, Ondrej
Vau, Nuno
Giannatempo, Patrizia
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (06)
[25] Real-world management and outcomes of older patients with locally advanced esophageal squamous cell carcinoma: a multicenter retrospective study
Saito, Yuki
Hamamoto, Yasuo
Hirata, Kenro
Yamasaki, Makoto
Watanabe, Masaya
Abe, Tetsuya
Tsubosa, Yasuhiro
Hamai, Yoichi
Murakami, Kentaro
Bamba, Takeo
Yoshii, Takako
Tsuda, Masahiro
Watanabe, Masayuki
Ueno, Masaki
Kitagawa, Yuko
BMC CANCER, 2023, 23 (01)
[26] Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma
McGregor, Bradley
Geynisman, Daniel M.
Burotto, Mauricio
Porta, Camillo
Suarez, Cristina
Bourlon, Maria T.
Del Tejo, Viviana
Du, Ella X.
Yang, Xiaoran
Sendhil, Selvam R.
Betts, Keith A.
Huo, Stephen
ONCOLOGIST, 2023, 28 (01) : 72 - 79
[27] First-Line Immuno-Oncology Combinations for Metastatic Clear Cell Renal Cell Carcinoma (mRCC): A Systematic Review of Phase III Clinical Trials
Hahn, Andrew W.
Shah, Amishi Y.
Campbell, Matthew T.
KIDNEY CANCER, 2021, 5 (04) : 207 - 217
[28] Real-world Effectiveness and Safety of Pazopanib in Patients With Intermediate Prognostic Risk Advanced Renal Cell Carcinoma
Procopio, Giuseppe
Bamias, Aristotelis
Schmidinger, Manuela
Hawkins, Robert
Rodriguez Sanchez, Angel
Vazquez Estevez, Sergio
Srihari, Narayanan
Kalofonos, Haralabos
Bono, Petri
Babanrao, Chaitali
Hirschberg, Yulia
Dezzani, Luca
Ahmad, Qasim
Suarez Rodriguez, Cristina
Jonasch, Eric
CLINICAL GENITOURINARY CANCER, 2019, 17 (03) : E526 - E533
[29] Impact of Immunotherapy on Real-World Survival Outcomes in Metastatic Renal Cell Carcinoma
Poprach, Alexandr
Kiss, Igor
Stanik, Michal
Barusova, Tamara
Pospisilova, Lenka
Fiala, Ondrej
Kopecky, Jindrich
Richter, Igor
Melichar, Bohuslav
Studentova, Hana
Lakomy, Radek
Holanek, Milos
Rozsypalova, Aneta
Zemankova, Anezka
Svoboda, Marek
Buchler, Tomas
TARGETED ONCOLOGY, 2023, 18 (06) : 893 - 903
[30] Radiotherapy plus pembrolizumab for advanced urothelial carcinoma: results from the ARON-2 real-world study
Rizzo, Mimma
Soares, Andrey
Grande, Enrique
Bamias, Aristotelis
Kopp, Ray Manneh
Lenci, Edoardo
Buttner, Thomas
Salah, Samer
Grillone, Francesco
de Carvalho, Icaro Thiago
Tapia, Jose Carlos
Gucciardino, Calogero
Pinto, Alvaro
Mennitto, Alessia
Abahssain, Halima
Rescigno, Pasquale
Myint, Zin
Takeshita, Hideki
Spinelli, Gian Paolo
Popovic, Lazar
Vitale, Maria Giuseppa
Fiala, Ondrej
Giannatempo, Patrizia
Zakopoulou, Roubini
Carrozza, Francesco
Massari, Francesco
Monteiro, Fernando Sabino Marques
Pace, Maria Paola
Giannini, Massimo
Roviello, Giandomenico
Porta, Camillo
Battelli, Nicola
Kanesvaran, Ravindran
Santoni, Matteo
SCIENTIFIC REPORTS, 2024, 14 (01):

← 1 2 3 4 5 →